SCHEMBL29843892

SCHEMBL29843892

CC1(OC(=O)N2CCC(CCCOc3ccc(CC(=O)N4CC(CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C4)c(F)c3)CC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 20/20 0.54
▸ KCNH2 Q12809 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23214779 1.00 GPR119 (0.54) GPR119KCNH2
SCHEMBL23214778 1.00 GPR119 (0.54) GPR119KCNH2
SCHEMBL23226189 0.90 GPR119 (0.46) GPR119KCNH2
SCHEMBL29843718 0.90 GPR119 (0.46) GPR119KCNH2
SCHEMBL23214773 0.90 GPR119 (0.46) GPR119KCNH2
SCHEMBL23214772 0.90 GPR119 (0.46) GPR119KCNH2
SCHEMBL23215668 0.90 GPR119 (0.43) GPR119KCNH2
SCHEMBL29843726 0.90 GPR119 (0.43) GPR119KCNH2
SCHEMBL23215665 0.90 GPR119 (0.43) GPR119KCNH2
SCHEMBL28846424 0.89 GPR119 (0.40) GPR119KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041722-A1 GPR119 AGONISTS Kallyope, Inc. (US) 2022-08-17 — — EP claimed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 — — US disclosed
US-11512065-B2 GPR119 agonists KALLYOPE, INC. (US) 2022-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512065-B2 GPR119 agonists GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885
US-20230061736-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback